Kumar Neil 4
4 · BridgeBio Pharma, Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
BridgeBio (BBIO) CEO Neil Kumar Sells $2.00M in Shares
What Happened Neil Kumar, CEO of BridgeBio Pharma, sold a total of 28,053 shares in open-market transactions on February 19, 2026, generating roughly $2,002,718 in proceeds. The sales were: 18,923 shares at $71.03 ($1,344,190); 8,528 shares at $72.08 ($614,702); and 602 shares at $72.80 ($43,826). These were dispositions (sales), not purchases.
Key Details
- Transaction date: February 19, 2026 (reported on Form 4 filed February 23, 2026). Filing appears timely under Section 16 rules.
- Prices and values: 18,923 @ $71.03; 8,528 @ $72.08; 602 @ $72.80 — total proceeds ≈ $2,002,718.
- Total shares sold: 28,053.
- Shares owned after transaction: Not specified in the provided filing disclosure.
- Notable footnotes:
- Sale effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.
- Footnotes list weighted-average price ranges for the sales and offer to provide per-price detail to the SEC, issuer, or shareholders on request.
- Reporting person disclaims beneficial ownership except to extent of pecuniary interest (standard disclaimer in filing).
Context
- These were routine sales under a pre-established 10b5-1 plan, which typically allows insiders to sell shares at pre-set times regardless of current company news. Sales are not, by themselves, evidence of the insider’s view on the company’s prospects.
Insider Transaction Report
Form 4
Kumar Neil
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-19$71.03/sh−18,923$1,344,190→ 243,581 total - Sale
Common Stock
[F1][F3]2026-02-19$72.08/sh−8,528$614,702→ 235,053 total - Sale
Common Stock
[F1][F4]2026-02-19$72.80/sh−602$43,826→ 234,451 total
Holdings
- 675,686(indirect: By Trust)
Common Stock
[F5] - 4,478,447(indirect: By Trust)
Common Stock
[F5]
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- [F2]Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F4]Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Signature
/s/ Will Solis, Attorney-in-Fact|2026-02-23